What is Ultragenyx known for?
Ultragenyx Pharmaceutical Inc. is widely recognized as a specialized American biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapeutic products designed specifically for treating rare and ultra-rare genetic disorders. These conditions typically suffer from a severe lack of approved medical treatments and represent high unmet medical needs globally. The organization strategically focuses its research pipeline across multiple complex disease categories, including serious metabolic disorders, bone and mineral conditions, endocrine diseases, muscle disorders, and central nervous system complications. By employing diverse drug development modalities such as advanced biologics, small molecules, gene therapies, antisense oligonucleotides, and messenger RNAs, Ultragenyx strives to transform the lives of patients suffering from debilitating congenital conditions. The firm has successfully brought several innovative treatments to market, such as therapies for X-linked hypophosphatemia and long-chain fatty acid oxidation disorders, while actively managing an extensive portfolio of clinical-stage candidates in collaboration with international partners and research institutions.
Related FAQs
UMB Bank provides digital banking platforms, mobile apps, and electronic funds transfer services that allow personal and business clients to manage their finances securely.
UniBank institutions encompass several prominent financial entities, most notably UniBank operating in Massachusetts, which carries a deep community heritage spanning over 150 years, tracing its ultimate roots back to the 1870 founding of the Whit...
Urban Outfitters, Inc.
Watsco, Inc. is the largest distributor of heating, ventilation, air conditioning, and refrigeration equipment, parts, and supplies in the North American market.
Employee remuneration at UniFi varies extensively depending on regional operational hubs, functional departments, and individual technical roles spanning software engineering, financial accounting, and administrative services.
Evaluating whether securities associated with specific ticker symbols or placeholder names represent attractive investments requires confirming the exact corporate entity and stock exchange under review.
Ultragenyx Pharmaceutical, traded under the ticker RARE, generally receives mixed buy and hold consensus ratings from biotechnology sector analysts.
Biotechnology professionals and clinical researchers often view Ultragenyx Pharmaceutical as a deeply purposeful and mission-driven organization dedicated to developing life-changing treatments for patients with rare genetic disorders.
Evaluating whether Ultragenyx Pharmaceutical represents a worthwhile equity purchase involves weighing its robust clinical pipeline and regulatory milestone catalysts against typical biotechnology market volatility and ongoing net operating losses...
Ultragenyx Pharmaceutical operates strictly as a specialized biopharmaceutical enterprise focused on discovering, developing, and commercializing novel biology-based therapies for patients suffering from severe, ultra-rare genetic diseases.
Ultragenyx Pharmaceutical focuses aggressively on clinical trial advancement, research and development expansion, and commercial product scaling, which means it has historically operated at a net loss under GAAP accounting standards.
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel therapies for rare and ultra-rare genetic diseases, receives extensive research tracking from dedicated healthcare and biotechnology equity analysts.
Treating ultra-rare genetic conditions requires highly specialized biotechnology and pharmaceutical enterprises focused on orphan drugs and niche therapeutic development.
Ultragenyx Pharmaceutical focuses on developing and commercializing novel, life-transforming therapeutics for rare and ultra-rare genetic and metabolic diseases.
Emil Kakkis (born 1960) is a highly accomplished American medical geneticist, widely recognized for his pioneering work in developing treatments for ultra-rare diseases. He holds an MD and Ph.D.
Ultragenyx Pharmaceutical Inc. (RARE) equity research analysts maintain positive multi-year consensus price targets reflecting its commercial portfolio scaling in rare and ultra-rare genetic diseases.
Wall Street research analysts covering Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. reports a trailing twelve-month revenue of approximately $660 million USD (translating to over ₹55 billion in international financial metrics), reflecting robust multi-year operational growth.
Ultragenyx Pharmaceutical fosters a patient-centric, mission-driven corporate culture focused on developing rare and ultra-rare genetic disease treatments.
Ultragenyx Pharmaceutical develops and commercializes advanced therapies targeting rare and ultra-rare genetic diseases.